Pediatric Gastroenterology, Hepatology & Nutrition

대한소아소화기영양학회 (The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition)
권호 표지
DOI QR코드

DOI QR Code

복통의 약물 요법 -복통과 연관된 기능성 위장관 질환을 중심으로

Pharmacological Treatment for Functional Abdominal Pain in Children

  • 투고 : 2009.10.31
  • 심사 : 2009.11.06
  • 발행 : 20091100
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Functional gastrointestinal disorders are among the most common medical problems in children. Abdominal pain-related functional gastrointestinal disorders can be categorized as functional dyspepsia, irritable bowel syndrome, abdominal migraine and childhood functional abdominal pain according to the Rome III criteria for pediatric functional gastrointestinal disorders. The aim of this paper was to examine the evidence supporting the use of the range of therapeutic options available for functional gastrointestinal disorders.

키워드

참고문헌

  1. Scholer SJ, Pituch K, Orr DP, Dittus RS. Clinical outcomes of children with acute abdominal pain. Pedatrics 1996;98:680-5.
  2. Apley J, Naish N. Recurrent abdominal pains: a field survey of 100 school children. Arch Dis Child 1958;50: 429-36.
  3. Faull C, Nicol AR. Abdominal pains in six-year olds: an epidemiological study in a new town. J Child Psychol Psychiatry 1986;27:251-60.
  4. Jeffrey S, Hyams MD, Burke G, Patricia M, Davis RN, Rzepski B, et al. Abdominal pain and irritable bowel syndrome in adolescents: A community-based study. J Pediatr 1996;129:220-6. https://doi.org/10.1016/S0022-3476(96)70246-9
  5. Dapoigny M, Bellanger J, Bonaz B, Bruley des Varannes S, Bueno L, Coffin B, et al. Irritable bowel syndrome in France: a common, debilitating and costly disorder. Eur J Gastroenterol Hepatol 2004;16:995-1001. https://doi.org/10.1097/00042737-200410000-00008
  6. Enck P, Klosterhalfen S. The placebo response in functional bowel disorders: perspectives and putative mechanisms. Neurogastroenterol Motil 2005;17:325-31. https://doi.org/10.1111/j.1365-2982.2005.00676.x
  7. Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther 2006;24:183-205. https://doi.org/10.1111/j.1365-2036.2006.02938.x
  8. Allescher HD, Bockenhoff A, Knapp G, Wienbeck M, Hartung J. Treatment of non-ulcer dyspepsia: a metaanalysis of placebo-controlled prospective studies. Scand J Gastroenterol 2001;36:934-41.
  9. Walker WA, Olivier G, Kleinman RE. Pediatric gastrointestinal disease. 4th ed. Hamilton: BC Decker; 2004.
  10. 정수진. 소아 만성 복통의 진단적 평가 - 기능성 복통과 의 감별점을 중심으로. 대한소아소화기영양학회지 2008;11(Suppl 2):S19-S28.
  11. Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006;130: 1527-37. https://doi.org/10.1053/j.gastro.2005.08.063
  12. Chitkara DK, Di Lorenzo C. Pharmacotherapy for functional gastrointestinal disorders in children. Current Opinion in Pharmacology 2006;6:536-40. https://doi.org/10.1016/j.coph.2006.06.008
  13. Huertas-Ceballos A, Logan S, Bennett C, Macarthur C. Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database Syst Rev 2008(1):CD003017.
  14. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006(4):CD001960.
  15. See MC, Birnbaum AH, Schechter CB, Goldenberg MM, Benkov KJ. Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment. Dig Dis Sci 2001;46:985-92. https://doi.org/10.1023/A:1010793408132
  16. 서지현. 소아의 기능성 장질환에서 사용하는 소화기계 약물의 종류:위장관 조절제. 대한소아소화기영양학회지 2008;11(Suppl 1):S30-S37.
  17. Sanger GJ, Alpers DH. Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterol Motil 2008;20:177-84. https://doi.org/10.1111/j.1365-2982.2008.01084.x
  18. Ruth M, Hamelin B, Rohss K, Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998;12:35-40. https://doi.org/10.1046/j.1365-2036.1998.00268.x
  19. Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res 1997;25:225-46.
  20. Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97(11 Suppl):S7-S26. https://doi.org/10.1016/S0002-9270(02)05657-5
  21. Goettsch WG, van den Boom G, Breekveldt-Postma NS, Smout AJ, Herings RM. Treatment patterns and health care costs of mebeverine-treated IBS patients: a casecontrol study. Pharmacoepidemiol Drug Saf 2004;13: 803-10. https://doi.org/10.1002/pds.997
  22. Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005(2):CD003460.
  23. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984;29:239-47. https://doi.org/10.1007/BF01296258
  24. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol 1987;130:81-4.
  25. Efskind PS, Bernklev T, Vatn MH. A double-blind placebo- controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996;31:463-8. https://doi.org/10.3109/00365529609006766
  26. Pulling M, Surawicz CM. Loperamide use for acute infectious diarrhea in children: safe and sound? Gastroenterology 2008;134:1260-2.
  27. Milo R. Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome. Curr Med Res Opin 1980;6:577-84. https://doi.org/10.1185/03007998009109491
  28. Fielding JF. Domperidone treatment in the irritable bowel syndrome. Digestion 1982;23:125-7. https://doi.org/10.1159/000198701
  29. Grover M, Drossman DA. Psychotropic agents in functional gastrointestinal disorders. Curr Opin Pharmacol 2008;8:715-23. https://doi.org/10.1016/j.coph.2008.07.012
  30. Jick H, Kaye JA, Jick SS. Antidepressants and the Risk of Suicidal Behaviors JAMA 2004;292:338-43. https://doi.org/10.1001/jama.292.3.338
  31. Russell G, Abu-Arafeh I, Symon DN. Abdominal migraine: evidence for existence and treatment options. Paediatr Drugs 2002;4:1-8.
  32. Worawattanakul M, Rhoads JM, Lichtman SN, Ulshen MH. Abdominal migraine: prophylactic treatment and follow-up. J Pediatr Gastroenterol Nutr 1999;28:37-40. https://doi.org/10.1097/00005176-199901000-00010
  33. Sadeghian M, Farahmand F, Fallahi GH, Abbasi A. Cyproheptadine for the treatment of functional abdominal pain in childhood: a double-blinded randomized placebocontrolled trial. Minerva Pediatr 2008;60:1367-74.
  34. Symon DN, Russell G. Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine. Arch Dis Child 1995;72:48-50. https://doi.org/10.1136/adc.72.1.48
  35. Camilleri M, Bueno L, de Ponti F, Fioramonti J, Lydiard RB, Tack J. Pharmacological and Pharmacokinetic Aspects of Functional Gastrointestinal Disorders. Gastroenterology 2006;130:1421-34. https://doi.org/10.1053/j.gastro.2005.08.062